Compare YSWY & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YSWY | FDMT |
|---|---|---|
| Founded | 2015 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 764.2M | 695.3M |
| IPO Year | 2021 | 2019 |
| Metric | YSWY | FDMT |
|---|---|---|
| Price | $24.74 | $11.88 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 12 |
| Target Price | ★ $29.63 | $28.09 |
| AVG Volume (30 Days) | 248.9K | ★ 971.2K |
| Earning Date | 11-12-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.79 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $85,209,000.00 |
| Revenue This Year | $23.20 | N/A |
| Revenue Next Year | N/A | $55.65 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 230194.60 |
| 52 Week Low | $18.92 | $6.96 |
| 52 Week High | $26.34 | $16.93 |
| Indicator | YSWY | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | 65.76 | 44.00 |
| Support Level | $18.92 | $8.68 |
| Resistance Level | $26.34 | $11.96 |
| Average True Range (ATR) | 0.93 | 0.94 |
| MACD | 0.24 | 0.04 |
| Stochastic Oscillator | 87.61 | 44.43 |
Yesway Inc is a U.S.-based convenience store operator that manages retail locations under the Yesway and Allsup's brands. Its stores offer foodservice products, grocery items, and private-label products. The company operates in rural and suburban markets across the Southwest and Midwest regions of the United States. It derives its revenue in the United States by operating convenience stores that offer merchandise, fuel, and other products and services designed to appeal to the convenience needs of the customers.
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).